InpharmD

This month, the following drugs were approved by the U.S Food and Drug Administration (FDA).

Read our clinical summaries on new approvals here:
https://inpharmd.com/blogs

Have you heard our latest Evidence Based Medicine (EBM) podcast?

There has been a ton of buzz around GLP-1s and their impact/benefit on other disease states and conditions.

Check out our latest episode evaluating the SURMOUNT-OSA trials and assessing tirzepatide for sleep apnea:

Spotify: https://open.spotify.com/episode/105QEYwjZgEpGTDMWyIxYe?si=7178abde82e946d9

Apple: https://podcasts.apple.com/us/podcast/evidence-based-medicine-presented-by-inpharmd/id1527752446?i=1000663472507

Have a topic suggestion for an episode? Tell us in the comments!

Read InpharmD's clinical summaries on newly approved FDA medications for the month of July:

AHZANTIVE® (aflibercept-mrbb)
https://inpharmd.com/blogs/new-fda-approval-ahzantive-aflibercept-mrbb

PYZCHIVA® (ustekinumab-ttwe)
https://inpharmd.com/blogs/new-fda-approval-pyzchiva-ustekinumab-ttwe

KISUNLA™ (donanemab-azbt)
https://inpharmd.com/blogs/new-fda-approval-kisunla-donanemab-azbt

EPYSQLI™(eculizumab-aagh)
https://inpharmd.com/blogs/new-fda-approval-epysqli-eculizumab-aagh

FEMLYV™ (ethinyl estradiol and norethindrone acetate)
https://inpharmd.com/blogs/new-fda-approval-femlyv-ethinyl-estradiol-and-norethindrone-acetate

InpharmD Annual Retreat!

A huge congrats to Atlanta Tech Village on their new office in Downtown! We had a blast seeing the new location!

We have four new FDA approval updates this week! Read the InpharmD summaries on our blog, links below.

1. Capvaxive™ - https://inpharmd.com/blogs/new-fda-approval

2. Vigafyde™ - https://inpharmd.com/blogs/new-fda-approval-vigafyde-vigabatrin-oral-solution

3. Yimmugo® - https://inpharmd.com/blogs/new-fda-approval-yimmugo-immune-globulin-intravenous-human-dira-liquid-for-intravenous-injection

4. Sofdra™ - https://inpharmd.com/blogs/new-fda-approval-sofdra-sofpironium

Single-dose rasburicase with frequent laboratory monitoring is effective in the management of TLS and offers significant cost reductions.

Read full response here: https://inpharmd.com/inquiries/15520

The FDA recently approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.

Read the InpharmD summary here: https://inpharmd.com/blogs/new-fda-approval-mresvia-respiratory-syncytial-virus-vaccine-mrna

Have you listened to our latest podcast? In this episode, we talk about excoriation (skin-picking) disorder and potential treatment options.

It's a unique subject, one that many might not be readily familiar with. It was particularly intriguing to discuss treatment approaches that combined pharmacological and behavioral therapy, leading to positive patient outcomes.

Tune in here:
Spotify – https://open.spotify.com/episode/0ydjUUjDYb7nlTx4mEgQKC?si=75fc29f5c0f3434b
Apple –
https://podcasts.apple.com/us/podcast/evidence-based-medicine-presented-by-inpharmd/id1527752446?i=1000657076814

As always, if you have any topics you'd like us to cover, send them in, and we'll do our best to get to them!

The FDA recently approved BKEMV™, the first biosimilar referencing Soliris (eculizumab) for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

BKEMV™ is the 53rd approved biosimilar and the 13th deemed interchangeable, allowing pharmacists to substitute it for Soliris without prior physician approval.

Read InpharmD's summary below:
https://inpharmd.com/blogs/new-fda-approval-bkemv-eculizumab-aeeb

The Food and Drug Administration (FDA) recently approved YESAFILI™(aflibercept-jbvf) and OPUVIZ™(aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept).

Both drugs are used to treat neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Read InpharmD's clinical summary here: https://inpharmd.com/blogs/new-fda-approvals-yesafili-aflibercept-jbvf-and-opuviz-aflibercept-yszy